TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Flow Augmentation Study in Postthrombotic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-thrombotic obstruction that requires percutaneous intervention through stenting, minimally 18 years of age~Exclusion Criteria:~* Peripheral arterial disease, comorbidities leading to impaired muscle function of either lower limb, co-morbidities affecting the circulatory system, history of deep venous surgery in either lower limb or groin, allergies to the plasters, pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Geko Device (Type: ACTIVE_COMPARATOR): Neuromuscular Stimulator
- IPCS (Type: ACTIVE_COMPARATOR): Intermittent Pneumotic Compression Stocking

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Compare Visual Outcomes Using a New Diagnostic Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent~* Patients of any gender, aged 18 years to open age~* Assured follow-up examinations~* Healthy eyes without clinically significant age-related cataract~  -Exclusion Criteria:~* Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial~* Patients whose freedom is impaired by administrative or legal order~* Concurrent participation in another drug or device investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients without clinically significant age-related cataract (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CPPS NIH III (symptoms over 3 months during the last 6 months, 4 glass-test)~* Pain Score ≥ 4~Exclusion Criteria:~* During the last month: intake of antibiotics, alpha receptor blockers, anticholinergics; intake of analgesics containing opioids (longer than 4 days); participating in a different clinical trial~* During the last 3 months:documented urinary infection, epididymitis, positive urinary culture; status post biopsy of the prostate gland; STD: Gonorrhea, Chlamydia, Mycoplasm, Trichomonads~* During the last 6 months: Finasteride or any other 5α-reductase inhibitor~* During the last 12 months: status post any surgery on the prostate gland; genital herpes; not adjustable hypertension, angina pectoris, heart failure (NYHA III-IV), Status post myocardial infarction, coronary bypass surgery or coronary dilatation~* During the last 24 months: cerebral insult, TIA; active disease of the liver~* Other urological diseases like prostate cancer, bladder cancer, status post radiation of the small pelvis, chemotherapy (intravesical or systemic)~* Urinary catheter~* Residual urine \> 200ml~* Serum creatinine \> 200µmol/l~* Status post injection of BTX A, hypersensitivity concerning any substances of content of BTX, myasthenia gravis~* Any kind of cancer~* Active inflammation (except the prostate gland)~* Neurological or psychological disease making signing of a consent form or behaving according to a study protocol impossible~* Abuse of drugs or alcohol during last 5 years~* Any disease that may influence the results according to the opinion of the medical doctor

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
- 2 (Type: PLACEBO_COMPARATOR): 4ml NaCl 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients at MGH Center for Pain Medicine who have clinical indication for undergoing diagnostic medial branch block of nerves to facet joints.~Exclusion Criteria:~* contraindication to the clinical procedure~* do not speak English

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- normal saline (Type: PLACEBO_COMPARATOR): None
- lidocaine (Type: ACTIVE_COMPARATOR): None
- alkalinized lidocaine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vascular Function Before vs After Smoking an E-cigarette as Compared to a Normal Cigarette

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* • Subjects must be males between 22 and 35 years of age, inclusive.~  * Subjects must be able to comprehend, sign and date a written informed consent prior to entering the study.~ * Subjects must be willing and able to comply with the protocol requirements for the duration of the study.~ * Subjects must have experienced one of the following:~    * Smoked for at least the last 4 years and at least 5 cigarettes a day or 1 pack-years,~   * Never having regularly smoked, i.e. \< 20 cigarettes in their lifetime and not in last 5 years.~Exclusion Criteria:~* Consumption of cigars, other tobacco and nicotine products and light-cigarettes (less than 8 mg ISO tar).~  * Exhaled CO levels \< 10 ppm (smokers) and ≥ 10 ppm (never smokers).~ * Urinary cotinine \< 200 ng/ml for smoker group~ * Treatment for arterial hypertension, or clinic blood pressure ≥140/90 mmHg.~ * Body mass index ≥ 30 kg/m2~ * Ocular diseases, glaucoma.~ * Convulsive disorder/epilepsy or intake of anticonvulsant drugs.~ * Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG, abnormal laboratory tests. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.~ * Prior participation in a clinical study in last 4 weeks.~ * Intake of drugs with potential impact on the endothelial function resp. autonomic nervous system.~ * Known intolerance against salbutamol, nitroglycerin and/or propylene glycol.~ * Regular intake of vitamins and mineral supplements.~ * Heavy exercisers and trained athletes (\> 5 hours physical activity / week).

- Gender: MALE
- Minimum Age: 22 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Smoker_1 (Type: None): Begins with e-cigarette crosses over to conventional cigarette
- Non smoker (Type: None): never smoking participants as control group
- Smoker_2 (Type: None): Begins with conventional cigarette crosses over to e-cigarette

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy Outcomes and Maternal Insulin Sensitivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy singleton pregnant women (10-12 weeks of gestation)~* BMI ≥25 kg/m2~* FPG ≤7.0 mmol/l~* Dutch or English speaking~* Written informed consent~Exclusion Criteria:~* Serious health complications (Hypertension, Hyperlipidemia, Asthma, Haemochromatosis) or medication use that influence the glucose metabolism or fetal growth (e.g. corticosteroids).~* Multiple pregnancy~* pre-existing Diabetes type 1 and 2 defined as FPG ≥7.0 mmol/l or use of diabetes medication~* Participation in any other studies involving the investigation of medication or nutritional products or severe illness or antibiotic use in the two weeks prior to entry into the study~* HIV/Hepatitis~* Expectation of non-compliance to the study protocol, among others, a fear of needles~* Known allergies or intolerances for one or more nutritional ingredients in the MTT~* Psychological dysfunctions

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: None

Study Arms:
- Healthy women pregnant of singleton with a BMI ≥25 kg/m2 (Type: None): Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women ≥18 to \<80 years of age who present with any one of the following:~* symptoms of Acute Coronary Syndromes (ACS)~* clinical symptoms of angina, or a positive stress test or who return for routine follow up angiography post stent placement in whom co-administration of aspirin and a thienopyridine (that is, clopidogrel, ticlopidine, or prasugrel) is not contraindicated~Exclusion Criteria:~* Those presenting with ST-elevation MI (STEMI)~* histories of refractory ventricular arrhythmias~* an implanted defibrillator device~* congestive heart failure (NYHA Class III or above) within 6 months prior to screening~* significant hypertension~* subjects with a history or clinical suspicion of cerebral vascular malformations, transient ischaemic attack, or stroke~* bleeding disorders~* women known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- clopidogrel 600 mg (Type: ACTIVE_COMPARATOR): None
- prasugrel 60 mg (Type: ACTIVE_COMPARATOR): None
- prasugrel 30 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have cytologically/histologically proven pleural malignancy, or who have pleural effusion in the context of malignancy elsewhere~* The pleural effusion is at least moderate to massive and causes symptoms~* Ability to give informed written consent to the study~Exclusion Criteria:~* Age \<18 years old~* Bleeding tendency not readily correctable (platelet \< 100 x 10\^9, INR ≥1.5 after transfusion)~* Hydropneumothorax before drain insertion~* Moderate-heavy septations in the pleural effusion (defined as a collection with more than 4 septations visible at the maximally septated area)~* Clinical emergency that an urgent chest drain is required~* Allergy to local anesthesia agents~* Blindness~* History of pleurodesis on the same side of malignant pleural effusion requiring drainage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Seldinger chest drain 14F (Type: OTHER): Patients with seldinger chest drain 14F inserted
- Seldinger chest drain 8F (Type: ACTIVE_COMPARATOR): Patients with seldinger chest drain 8F inserted

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Substrate and Intervention Mechanisms for Persistent Atrial Fibrillation Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of persistent atrial fibrillation~* Indicated for an AF-ablation procedure~* Agree to participate in the trial~Exclusion Criteria:~* Are unable or unwilling to provide informed consent for the SIMPle AF study~* Patients with cardiac devices like pacemakers, internal cardiac defibrillators and Cardiac Resynchronization Therapy Device (CRT). Patients with acute or chronic renal insufficiency (glomerular filtration rate \<30 ml/min/1.73 m2), or patients in the perioperative liver transplantation period~* Pregnant women~* Patients who are unable to adhere to the follow up protocol~* Patients with contraindication to MRI, including ferromagnetic aneurysm clips, metal in the eye, and implanted ferromagnetic or other MRI-incompatible devices~* Patients in whom the LGE Cardiac MRI does not meet quality standards for fibrosis analysis~* Subjects without daily access to a smart phone or tablet compatible with the mobile-based application and ability to upload ECG tracings for the follow up period~* Patients with a history of allergic reactions to gadolinium-based contrast agents or ingredients and will not be premedicated\*\*~  * Subjects with a history of reaction to contrast may be premedicated according to institutional protocol prior to receiving intravenous contrast agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional PVI (Type: ACTIVE_COMPARATOR): Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
- PVI + Scar-based ablation (Type: EXPERIMENTAL): Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage \<0.3 mV.
- PVI + Modeling-predicted rotors ablation (Type: EXPERIMENTAL): Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All Vanderbilt University Medical Center IBD patients that are 18 years or older~* Those who volunteered to participate in this online web-based survey study.~Exclusion Criteria:~* Vanderbilt University Medical Center patients unable to take the survey because they do not have an e-mail address or access to one.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IBD patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic pulmonary embolism patients \>18 years~2. Availability of a baseline contrast-enhanced chest computed tomogram or conventional pulmonary angiogram with evidence of pulmonary embolus in at least one main or lobar pulmonary artery ≥ 6mm in diameter~3. Availability of a baseline transthoracic echocardiogram with sufficient image quality permitting the measurement of right ventricular (RV) and left ventricular (LV) dimensions in the apical or subcostal four-chamber view~4. Echocardiographic evidence of right ventricular dilatation with a subannular RV/LV ratio ≥ 0.9 from the apical or subcostal four-chamber view~5. Appropriate informed consent was obtained from the patient or legal representative~Exclusion Criteria:~1. Patient has underwent Cardiopulmonary Resuscitation (CPR) in the last 48 hours~2. Patient is participating in any other clinical study~3. Pregnancy, lactation or parturition within the previous 30 days (positive pregnancy test, women of childbearing age must be tested or use a medically accepted method of birth control)~4. Inability to comply with study Follow-up assessments (e.g. due to geographic)~5. Previous enrollment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AngioJet Ultra PE Thrombectomy System (Type: EXPERIMENTAL): Patients are treated with the AngioJet Ultra PE Thrombectomy System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically confirmed Breast cancer~* Metastatic Breast Cancer currently of stage IV disease or unresectable locoregionally recurrent breast cancer~* refractory to the most recent chemotherapy, documented by progression on or within six (6) months of therapy~* At least 14 days from the completion of any previous cancer therapy~* Adequate organ function~* Life expectancy of 3 months or more~* Willing and able to comply with the protocol and able to understand and willing to sign an informed consent~Key Exclusion Criteria:~* Previously treated with eribulin~* Peripheral neuropathy Grade ≥3~* Receipt of prior CXCR4 therapy~* Receipt of colony stimulating factors (CSFs) filgrastim, pegfilgrastim, or sargramostim, or radiation therapy within 14 days prior to study Day 1~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to balixafortide or eribulin or other agents used in the study~* Breast feeding or pregnant~* Patients with congestive heart failure, electrolyte abnormalities, bradyarrhythmias, known congenital long QT syndrome, QT interval corrected with Fridericia's formula (QTcF) ≥470 msec at baseline in the absence of bundle branch block, or currently taking drugs at known risk of prolonging the QT interval or causing torsades de pointes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eribulin (Type: ACTIVE_COMPARATOR): None
- Balixafortide + Eribulin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients with atrial fibrillation and an indication for oral anticoagulation (CHA2DS2-VASc score≥ 1).~* Current clopidogrel treatment~* Informed, written consent by the patient or her/his legally-authorized representative for participation in the study.~Key Exclusion Criteria:~* Age ≤18 years~* Cardiogenic shock~* Current therapy with dabigatran~* Patients with a recent thromboembolic event and high thromboembolic risk requiring bridging therapy with either unfractionated heparin or LMWH~* Contraindication for oral anticoagulation~* Active bleeding~* Known allergy or intolerance to the study medications: dabigatran, phenprocoumon

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Dabigatran Therapy
- Arm 2 (Type: ACTIVE_COMPARATOR): Phenprocoumon Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues